In non-small-cell lung cancer (NSCLC) (Figure 2B), Yeung et al., reported the activation of the YAP-MKK3/6-p38MAPK–STAT3 signaling pathway in the gefitinib-induced genomic instability involving transient tetraploidization [28] and gefitinib-resistance in NSCLC cells (HCC827GR, H1975). This evidence concerns the gene MAP2K3 and non-small cell lung carcinoma.